Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on November 14, 2011, to disclose the presentation of data from a Phase 1b study of its investigational drug REGN727/SAR236553. This study focused on patients with hypercholesterolemia, specifically those with heterozygous familial and non-familial forms of the condition. The data, presented at the American Heart Association Scientific Session 2011, demonstrated REGN727/SAR236553's ability to effectively reduce LDL-C (low-density lipoprotein cholesterol) when used as either a standalone therapy or as an add-on to existing treatments.
Key Highlights
- 1Presentation of Phase 1b study data for REGN727/SAR236553 at the American Heart Association Scientific Session 2011.
- 2REGN727/SAR236553 is an investigational monoclonal antibody targeting PCSK9.
- 3Study evaluated REGN727/SAR236553 in patients with heterozygous familial and non-familial hypercholesterolemia.
- 4Data showed effective reduction of LDL-C as both monotherapy and add-on therapy.
- 5The presentation slides are furnished as an exhibit (Exhibit 99.1) to the 8-K filing.
- 6This data is significant for investors as it pertains to a potential new treatment for high cholesterol, a widespread health concern.
Frequently Asked Questions
REGN727/SAR236553 is an investigational monoclonal antibody being developed by Regeneron. The data presented concerns its use in treating hypercholesterolemia, specifically heterozygous familial and non-familial forms, by inhibiting PCSK9 to lower LDL-C levels.
The Phase 1b study demonstrated that REGN727/SAR236553 effectively reduced LDL-C levels in patients with hypercholesterolemia. Importantly, it showed efficacy when used either alone (monotherapy) or in combination with other cholesterol-lowering treatments (add-on therapy).
Investors can find the detailed presentation slides by referring to Exhibit 99.1, titled 'Inhibition of PCSK9 with Monoclonal Antibody REGN727/SAR236553 Effectively Reduces LDL-C as Mono or Add-on Therapy in Heterozygous Familial and Non-Familial Hypercholesterolemia,' which is furnished with this Form 8-K filing.
No, the filing indicates that REGN727/SAR236553 is an investigational drug. The data presented is from a Phase 1b study, which is an early stage of clinical development. Further trials would be required for potential regulatory approval.